LIDEX
LOE ApproachingNDATOPICALCREAM
Approved
Jun 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
LIDEX by Alvogen is clinical pharmacology: mechanism of action: lidexagel® 5% gel releases lidocaine from a mild acidic vehicle to stabilize the neuronal membrane by inhibiting the ionic fluxes required for initiation and conduction of impulses, thereby effecting local anesthetic action. First approved in 1971.
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIDEX is a topical cream formulation approved in 1971 for dermatological indications. The specific mechanism of action and indication details are not documented in available data. This is a legacy NDA product currently approaching loss of exclusivity.
LOE Approaching
With LOE approaching and minimal current commercial data, the brand is in portfolio maintenance mode with limited growth opportunities and likely a smaller, specialized team.
Mechanism of Action
CLINICAL PHARMACOLOGY: Mechanism of Action: LidexaGel® 5% Gel releases lidocaine from a mild acidic vehicle to stabilize the neuronal membrane by inhibiting the ionic fluxes required for initiation and conduction of impulses, thereby effecting local anesthetic action. A mild acidic vehicle lowers…
Worked on LIDEX at Alvogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.